SUPRAMOLECULAR AGENTS AS RADIOTHERANOSTIC DRUGS

SMARTdrugs aims to revolutionize cancer treatment by developing supramolecular radiotheranostics that integrate diagnostics and therapy for targeted drug delivery.

Subsidie
€ 2.135.087
2024

Projectdetails

Introduction

From diagnostic applications in the quantification and characterisation of biomarker expression in cancer patients, through to molecularly targeted radionuclide therapy, radiopharmaceuticals are at the frontline of modern personalised medicine. The radical long-term vision of SMARTdrugs is to harness the untapped potential of supramolecular chemistry to create a new class of therapies - radiotheranostics - which combine both diagnostic and therapeutic radionuclides in one compound.

Methodology

By using the self-assembly of host-guest supramolecular coordination complexes and molecularly interlocked molecules as scaffolds for creating supramolecular radiotheranostic drugs, new methods for radiotheranostic synthesis that break away from conventional medicinal chemistry concepts will be introduced.

Proof of Concept

SMARTdrugs will establish a proof-of-concept demonstrating the utility of non-covalent systems in the design of multifunctional radiotheranostic agents with tailored pharmacokinetics, and their application in challenging drug-delivery scenarios including targeted delivery to cancers of the lung and brain.

Objectives

Our 3 main objectives are:

  1. Objective 1: Develop new chemical landscapes using non-covalent bonding to create functionalised supramolecular compounds for cancer-specific theranostics.
  2. Objective 2: Elucidate the key relationships between supramolecular radiotheranostics and the complex tumour microenvironment that determine drug efficacy in vivo.
  3. Objective 3: Perform head-to-head studies to establish a proof-of-principle that supramolecular chemistry is a viable alternative to classical radiopharmaceutical design.

Long-term Goals

The long-term goal is to establish a new chemical landscape for radiotheranostic design and to facilitate clinical translation of this new technology. Successful experiments will lay the foundations for exploiting supramolecular chemistry in the wider context of drug delivery and theranostics, and for studying biological interactions at the cellular to whole-organism levels.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 2.135.087
Totale projectbegroting€ 2.135.087

Tijdlijn

Startdatum1-1-2024
Einddatum31-12-2027
Subsidiejaar2024

Partners & Locaties

Projectpartners

  • TECHNISCHE UNIVERSITAET MUENCHENpenvoerder
  • UNIVERSITAIR MEDISCH CENTRUM UTRECHT
  • ASOCIACION CENTRO DE INVESTIGACION COOPERATIVA EN BIOMATERIALES- CIC biomaGUNE
  • UNIVERSITAT ZURICH
  • KING'S COLLEGE LONDON

Land(en)

GermanyNetherlandsSpainSwitzerlandUnited Kingdom

Vergelijkbare projecten binnen EIC Pathfinder

EIC Pathfinder

"Creation of innovative ""humidity to electricity"" renewable energy conversion technology towards sustainable energy challenge"

The CATCHER project aims to develop scalable technology for converting atmospheric humidity into renewable electricity, enhancing EU leadership in clean energy innovation.

€ 2.996.550
EIC Pathfinder

Quantitative Ultrasound Stochastic Tomography - Revolutionizing breast cancer diagnosis and screening with supercomputing-based radiation-free imaging.

The project aims to revolutionize breast cancer imaging by developing adjoint-based algorithms for uncertainty quantification, enhancing diagnostic confidence through high-resolution, radiation-free images.

€ 2.744.300
EIC Pathfinder

Dynamic Spatio-Temporal Modulation of Light by Phononic Architectures

Dynamo aims to revolutionize imaging technologies by enabling simultaneous light modulation at GHz rates, enhancing processing speed and positioning Europe as a leader in optical advancements.

€ 2.552.277
EIC Pathfinder

Emerging technologies for crystal-based gamma-ray light sources

TECHNO-CLS aims to develop novel gamma-ray light sources using oriented crystals and high-energy particle beams, enhancing applications in various scientific fields through innovative technology.

€ 2.643.187

Vergelijkbare projecten uit andere regelingen

ERC STG

Deciphering the radiobiology of targeted radionuclide therapy: from subcellular to intra-tumoural analyses

This project aims to enhance targeted radionuclide therapies for metastatic cancer by elucidating radiobiological mechanisms and developing advanced imaging techniques to improve treatment strategies.

€ 1.750.000
ERC POC

Remotely actuated re-shaped nanocarriers for tumour targeting

Developing remotely actuated, anisotropic metal/polymer hybrid nanoparticles for targeted drug delivery in cancer to enhance therapeutic efficacy and minimize side effects.

€ 150.000
ERC STG

Breaching the protective cancer stroma with radiotherapy-responsive liposomes

This project aims to enhance liposomal drug delivery in pancreatic cancer by integrating radiocatalytic nanomaterials for controlled drug release and improved tissue permeability through radiotherapy.

€ 1.942.158
ERC COG

Development of Suprasensors and Assays for Molecular Diagnostics

SupraSense aims to develop advanced biomimetic sensors for detecting metabolites in biofluids, enhancing diagnostic selectivity and sensitivity for early disease detection.

€ 1.994.069